"

亚搏体育客户端app-亚搏体育官方网站app-亚搏手机版app官网下载拥有全球最顶尖的原生APP,每天为您提供千场精彩体育赛事,亚搏体育客户端app-亚搏体育官方网站app-亚搏手机版app官网下载更有真人、彩票、电子老虎机、真人电子竞技游戏等多种娱乐方式选择,亚搏体育客户端app-亚搏体育官方网站app-亚搏手机版app官网下载让您尽享娱乐、赛事投注等,且无后顾之忧!

                  "
                  Latest news from group

                  About us

                  Innovation-Driven Development Based on Core Businesses

                  Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997.

                  After receiving approval by the China Securities Regulatory Commission in August 1999, the company issued 58 million A shares on the open market. In October, the company's shares were then listed on the Shanghai Stock Exchange. As of the end of 2018, the company had 960 million yuan in registered capital and total assets of 10 billion yuan.


                  Company profile

                  Zhejiang Medicine currently has nine major subsidiaries, including Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, Zhejiang Health Creation Biotechnology Co., Ltd., Zhejiang LaiYi Medicine Co., Ltd., Zhejiang Novus Pharmaceuticals Co., Ltd., Zhejiang Changhai Pharmaceuticals Co., Ltd., Shanghai Vital Health Management Co., Ltd., NovoCodex Biopharmaceuticals. Co., Ltd., and two research units, the Pharmaceutical Industry Research Institute and the Shanghai Laiyi Biopharmaceutical R&D Center. The company has more than 6,800 employees, including more than 2,500 professional and technical personnel, who account for more than 37% of the company’s total number of employees.


                  01 / 06

                  At present, Zhejiang Medicine performs the specialized and large-scale production of fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products. The company's leading products, including its synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin all rank among the top worldwide. The company's preparations of injectable levofloxacin lactate (trade name "Lailixin"), injectable vancomycin hydrochloride injection (trade name "Laikexin"), and injectable teicoplanin (trade name "Jialixin") occupy important positions in the Chinese market.


                  Zhejiang Medicine adheres to a development strategy of "Innovation and Entrepreneurship, Competitive Development, Advanced Development, and Strength through Talent". The company focuses on product development, places great importance on restructuring, integrates a number of resources, strengthens indigenous technology innovation and technology innovation to produce the best possible products, performs high-level DMF file registration and FDA certification procedures, vigorously promotes clean production and the circular economy, is building a complete market network from a global perspective, and has developed a positive brand image and advanced corporate culture, thus enhancing the company’s core competitiveness. At present, Zhejiang Medicine has developed into a technologically-advanced, large-scale, and globally influential and competitive pharmaceutical company.


                  Play video